Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Cell Therapy Deals A "Strategic Priority" For Shire

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

The recent earnings season was a reminder that Shire PLC, along with other specialist drug developers such as Celgene Inc., are comfortably positioned in a high-revenue-growth world that most big pharma have forgotten about.

You may also be interested in...



Disappointing Provenge Sales Stir Doubts About Demand

Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.

Advanced BioHealing To Bring Regeneration To Shire

The evening before Advanced BioHealing Inc. was set to debut on the New York Stock Exchange on May 18, it announced that Shire PLC has agreed to buy it for $750 million.

U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes

The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.

Table

View full table

Related Content

In Vivo

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS004801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By